Recursion Pharmaceuticals, Inc. (RXRX) Misses Q2 EPS by 2c

Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) reported Q2 EPS of ($0.40), $0.02 worse than the analyst estimate of ($0.38). Revenue for the quarter came in at $14.42 million versus the consensus estimate of $11.96 million.

For earnings history and earnings-related data on Recursion Pharmaceuticals, Inc. (RXRX) click here.

You May Also Be Interested In

• Raymond James Downgrades Phreesia Inc. (PHR) to Market Perform
• CANEX Metals raises C$6.5M, with C$3M from largest shareholder
• Healwell's Darwen AI to match clinical trials to 100K+ consented patients